Similar articles

Abstract: Objective: to report the application of GPIIb/IIIa antagonist (integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in Chinese. Method: Twenty-one patients who underwent percutaneous transluminal catheter angioplasty(PTCA) and stent implantation were included. After arterial puncture, integrilin was injected at dose of 180 μg/kg, and then maintained at 2 μg/kg·min for 18 hours. Asprine, plavix(clopidogrel) and heparin were used at the same time. ACT, PT, KPTT and blood routine were routinely monitored. Results: All sheaths were drawn out 2 to 4 hours after the procedure.. There was no severe complication such as hematoma, acute and subacute thrombosis in coronary artery, or thrombocytopenia. ACT returned to less than 150 seconds in 2 hours in 15 patients; in 4 hours in 6 patients. There was no significant difference between the pre- and post-procedure value of PT and platelet count. KPTT was significantly higher than pre-procedure value at 2 hours after the procedure. No recurrence of angina pectoris was observed in the first nine patients within one year follow-up, and no restenosis occurred in stents in the five patients who had coronary angiography one year later. Conclusion: Application of GPIIb/IIIa receptor antagonist (integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in combination with aspirin and plavix could significantly reduce the dosage and duration of heparin with benefit of shortening the indwelling time of sheaths, but did not increase risk of bleeding or lead to thrombosis in stent.

[1] Frishman, W.H., Burns, B., Atac, B, et al.,1995. Novel antiplatelet therapies for treatment of patients with ischemic heart disease. Am Heart J, 130(4): 877-92.

[2] Kereiakes, D.J., 1998. Preferential benefits of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state. Am J cardiol, 81(7A): 49E-54E.

[3] Pitts, W.R., Lange, R A., 1999. Platelet glycoprotein IIb/IIIa receptor blockade: lessening the risk of coronary interventions. Thromb Haemost, 82 (suppl 1):136-138.